The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Drug Manufacturers - Major > Pharmacia Corporation

Pharmacia Corporation
NYSE: PHA
Change
symbol:
     
 NEWS FROM THE WIRES
Anti-arthritis drugmakers take hit after study
Aug 22 2001 09:48 AM PDT

U.S. tech stocks slump, blue chips flat
Aug 10 2001 08:57 AM PDT

WRAPUP 2-Asian shares drift in themeless trade, yen dips
Aug 10 2001 02:57 AM PDT

WRAPUP 2-Asian shares drift in themeless trade, yen dips
Aug 10 2001 02:56 AM PDT

Arthritis drug studied as lung cancer preventative
Jul 31 2001 05:46 PM PDT

More WIRE STORIES about this company

 NEWS FROM THE STANDARD
Tech Shares Gain
Aug 23 2001 10:44 AM PDT

Midday Market Movers: Techs Are Not the Only Drag
Jun 22 2001 10:13 AM PDT

Six Degrees of Co-optation
Jun 26 2000 12:00 AM PDT

Slow Liftoff For Online Tech Transfer
Jun 12 2000 12:00 AM PDT

Lesson No. 1: A Negotiation Is Not a Deal
May 29 2000 12:00 AM PDT

 PROFILE
Pharmacia, the result of a merger between drugmaker Pharmacia & Upjohn and life sciences giant Monsanto, has entered the major leagues. The merger puts Pharmacia among the world's top drug firms and moves it away from the increasingly unpopular life sciences; it also provides a stronger sales force, a broader product base, and a bigger pipeline. Pharmacia gets almost one-third of its sales from subsidiary Monsanto's agricultural products; drugs (arthritis best-seller Celebrex, panic treatment Xanax) and over-the-counter remedies (Rogaine, Nicorette) make up the rest. The company has sold almost 15% of Monsanto to the public; it has also sold the rights to sweetener NutraSweet and lawn and garden product line ORTHO.

 COMPETITION
American Home Products Corporation (AHP)
AstraZeneca PLC (AZN)
Novartis AG (NVS)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 18,144.00
1-Yr. Sales Growth: 98.4%
Employees: 59,000
Revenue per employee: $307,525.42

 KEY PEOPLE
• Fred Hassan
    CEO
• Christopher J. Coughlin
    CFO

 CONTACT INFO
100 Rt. 206 N.
Peapack, NJ 07977
US
Phone: 908-901-8000
Fax: 908-901-8379
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001